Presentation is loading. Please wait.

Presentation is loading. Please wait.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

Similar presentations


Presentation on theme: ""Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices."— Presentation transcript:

1 "Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices & Radiological Health U.S. Food & Drug Administration (240)

2 1 What is a 510(k)  Premarket Notification  Section 510(k) of FF,D,&C Act  21 CFR 807 Subpart E  Submission for Device Premarket Review  Allows FDA to Make a Determination Regarding Substantial Equivalence (SE)  “The” classification process for a device

3 2 What a 510(k) Is Not  A Form  Establishment Registration (FDA-2891)  Device Listing (FDA-2892)  Premarket Approval (PMA)  Product Development Protocol (PDP)  Evaluation of Automatic Class III Designation (De Novo)

4 3 Medical Device Amendments of 1976 to the FF,D,&C Act  May 28, 1976  Defined a device (201(h) of the Act)  Required risk based classification of device types legally on the market  Led to classification of approximately 1,700 different generic types of devices and grouped into 19 medical specialties  Required premarket review of devices

5 4 Safe Medical Devices Act (SMDA)  1990 –513(i) Substantial Equivalence Defined –513(a)(1)(B) Special Controls

6 5 Food & Drug Modernization Act (FDAMA)  1997 –Redefined 510(k) Exemption Criteria for Class I –Added Class II Exemption Criteria –De Novo –SE w/Limitations –Class II Petitions for Exemption

7 6 510(k) & Classification  A 510(k) is the classification process for individual post-amendment devices by: –Finding the device substantially equivalent (SE) or –Finding the device not substantially equivalent (NSE)

8 7 510(k) & Classification  Determination regarding substantial equivalence: –NSE (For reasons other than lack of performance data)  PMA, PDP, or De Novo –NSE for lack of performance data  a new 510(k) may be submitted for review –SE  To Market

9 8 Substantially Equivalent (SE)  If: –In Comparison to a legally marketed device (that does not require PMA), it: Has the same intended use, and Has the same technological characteristics as the predicate device, Or

10 9  Has the same intended use, and  Has different technological characteristics and the information in the 510(k): –Does not raise a new question(s) of safety and effectiveness; and –Demonstrates it is at least as safe and effective as the predicate. Substantially Equivalent (SE)

11 10 510(k) & Classification  Finding the device not substantially equivalent (NSE): –automatically places device into class III and requires: PMA; Evaluation of Automatic Class III Designation (de novo); or Reclassification before marketing

12 11 Not Substantially Equivalent (NSE)  There is no predicate device; or  The device has a new intended use; or  The device has different technological characteristics compared to the predicate device and raises a new type question(s) of safety and effectiveness *All of the above require no review of data and will require PMA or De Novo.

13 12 Not Substantially Equivalent (NSE)  The data provided do not demonstrate that the device is at least as safe and effective as the predicate. *FDA usually asks for additional information at least once prior to determining the device is NSE for lack of data *The above NSE reason requires review of the data and would require submission of a new 510(k) with new data to demonstrate SE.

14 13  Approximately 80% are found SE  2 – 3% are found NSE  Remaining 510(k)s are usually withdrawn 510(k) & Classification

15 Evaluation of Automatic Class III Designation “de novo” Classification  Section 513(f)(2)  De novo received within 30 days of receipt of NSE letter (NSE reason for other than lack of performance data)  No predicate/“Low risk” devices  60-day review period  Extensions for submission of additional information granted

16 Evaluation of Automatic Class III Designation “de novo” Classification (cont.)  If approved, new device proceeds immediately to market  30 days after the signed approval order, notification is published in FR  New classification regulation established  New device becomes new classification/predicate  Next person may submit a 510(k) and use de novo as the predicate

17 16


Download ppt ""Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices."

Similar presentations


Ads by Google